Plasma Level of MicroRNAs, MiR-107, MiR-194 and MiR-210 as Potential Biomarkers for Diagnosis Intestinal-Type Gastric Cancer in Human

Abstract

Background: Timely and sensitive diagnosis of gastric cancer is crucial for efficient treatment and survival of the<br />patients. microRNAs have been considered as diagnostic biomarkers in different type of cancers including gastric cancer.<br />In the present study, the expression profile of four microRNAs, miR-103, miR-107, miR-194 and miR-210 were evaluated<br />in patients with intestinal-type of gastric cancer (IGC) in order to assess their diagnosis utility as noninvasive biomarkers.<br />Methods: A total number of 100 plasma samples from patients with gastric cancer and healthy controls were obtained<br />and total RNA was extracted using a commercial monophasic solution of phenol and guanidium thiocyanate. Reverse<br />transcription (RT) reactions were performed by specific stem-loop RT primers and M-MuLV RT-enzyme. The expression<br />patterns of microRNAs were assessed using reverse transcription quantitative real-time PCR (RT-qPCR) method and<br />the expression of SNORD47 RNA was used as the reference for normalization. Results: The results indicate that the<br />plasma levels of miR-107, miR-194, and miR-210 were significantly lower in patients. Receiver operating characteristic<br />(ROC) curve analysis showed that the patients could be distinguished from healthy individuals at the cutoff levels of<br />0.504, 0.266, and 0.394 of miR-107, miR-194, and miR-210, respectively. On the other hand, the expression levels of<br />these miRNAs were not significantly different in different clinicopathological stages of the disease. Conclusion: These<br />findings suggest that the plasma levels of miR-107, miR-194 and miR-210 were downregulated in patients with ICG<br />and propose these molecules as potential non-invasive biomarkers for detection of IGC.